EELS (Ethical, Economic, Legal & Social) Article
The Pharmacogenomics Journal (2006) 6, 154–157. doi:10.1038/sj.tpj.6500364; published online 17 January 2006
Pharmacogenomics and regulatory decision making: an international perspective
D L Mendrick1, C Brazell2, E A Mansfield3, R Pietrusko4, I Barilero5, J Hackett6, S Stürzebecher7 and D Jacobson-Kram8
- 1Toxicogenomics, Gene Logic Inc., Gaithersburg, MD, USA
- 2Genetics Research, GlaxoSmithKline, Middlesex, UK
- 3Regulatory Affairs, Affymetrix Inc., Santa Clara, CA, USA
- 4Worldwide Regulatory Affairs, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA
- 5Global Regulatory Policy and Intelligence, Johnson & Johnson Pharmaceutical Research and Development, High Wycombe, Bucks, UK
- 6Office of In Vitro Diagnostic Device Evaluation and Safety, CDRH, Rockville, MD, USA
- 7Corporate Preclinical Development, Schering AG, Berlin, Germany
- 8Office of New Drugs, CDER, Rockville, MD, USA
Correspondence: DL Mendrick, Toxicogenomics, Gene Logic Inc., 610 Professional Drive, Gaithersburg, MD 20879, USA. E-mail: dmendrick@genelogic.com
Top of page
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Cerebral blood flow response in adenosine 2a receptor knockout mice during transient hypoxic hypoxia
Journal of Cerebral Blood Flow & Metabolism Original Article
Journal of Investigative Dermatology Letter
